4710 Bellaire Boulevard
Suite 210
Bellaire, TX 77401
United States
832 742 1357
https://www.biopathholdings.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 10
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Peter H. Nielsen MBA | Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer | 696,24k | N/D | 1949 |
Mr. Douglas P. Morris | Co-Founder, Director of Investor Relations, Secretary & Director | 73,74k | N/D | 1956 |
Mr. Michael Hickey M.B.A. | VP of Clinical Operations | N/D | N/D | N/D |
Mr. Anthony Price | Senior Vice President of Finance, Accounting & Administration | N/D | N/D | N/D |
Dr. Ana Tari Ashizawa Ph.D., MBA | Senior Vice President of Research, Development & Clinical Design | N/D | N/D | N/D |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
L'ISS Governance QualityScore di Bio-Path Holdings, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.